Biotin-PEG3-OH
CAS No. 1263044-40-1
Biotin-PEG3-OH ( —— )
Catalog No. M26906 CAS No. 1263044-40-1
Biotin-PEG3-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 37 | Get Quote |
|
10MG | 55 | Get Quote |
|
25MG | 87 | Get Quote |
|
50MG | 133 | Get Quote |
|
100MG | 201 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBiotin-PEG3-OH
-
NoteResearch use only, not for human use.
-
Brief DescriptionBiotin-PEG3-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
DescriptionBiotin-PEG3-OH is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.(In Vitro):PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1263044-40-1
-
Formula Weight375.5
-
Molecular FormulaC16H29N3O5S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOCCOCCOCCNC(=O)CCCCC1SCC2NC(=O)NC12
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. I Hilgert, et al. Antitumour and immunosuppressive activity of hydroxyanthraquinones and their glucosides. Folia Biol (Praha). 1977;23(2):99-109.
molnova catalog
related products
-
EG1
EG1, a novel specific inhibitor of Pax2 transcription activation, targets the DNA binding domain and inhibits embryonic kidney development.
-
2-Amino-3-carboxy-1,...
2-Amino-3-carboxy-1,4-naphthoquinone is the electron transfer mediator, can change glucose metabolism of the homofermentative lactic acid bacteria.
-
Boc-NH-C6-Br
Boc-NH-C6-Br is a cleavable linker used for antibody-drug conjugates (ADC).